Pagoclone going the Zoloft way?
Executive Summary
Pfizer nearly rejected Zoloft clinical development twice before going on to market the drug, Indevus tells conference call on Pfizer's termination of pagoclone contract. "Twice in the history of Zoloft, in the early days at Pfizer, the compound was facing cancellation over dose and efficacy issues and obviously Zoloft came through to be one of the most successful antidepressants today," the company said...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.